ProKidney Is Soaring on Trial Results. How Should You Play Penny Stock PROK Here?
The company's candidate treatment did not exhibit any serious adverse events during the course of the mid-stage trial either – its press release confirmed on Tuesday.
This Analyst Just Raised His Broadcom Stock Price Target by 70%. Should You Buy AVGO Now?
Why Alibaba Stock Looks Like a Screaming Buy After Falling 27% From Its 2025 Highs
2 ETFs Offering Juicy Dividend Yields of 20% or Higher
Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else.
Including today's meteoric run, ProKidney stock is trading at roughly 740% from its year-to-date low set in April.
The REGEN-007 clinical trial update is significant for ProKidney investors since it clears the path for Rilparencel to advance into Phase 3 evaluation and eventually attempt to secure FDA approval.
Positive mid-stage data often leads to a significant increase in a biotech firm's valuation, attract institutional interest, and raise the likelihood of strategic partnerships or future funding.
This milestone position ProKidney, which targets chronic kidney disease, as a potential front-runner in renal regenerative medicine.
That's why PROK shares are ripping massively to the upside on Tuesday.
While the Rilparencel data reported this morning is positive for ProKidney, investors should note that it, nonetheless, is a penny stock with a market cap of just $177 million.
ProKidney shares, therefore, remain inherently risky to own – especially after today's cosmic run – as penny stocks often suffer from low liquidity and high volatility.
PROK stock is exposed to sharp price swings and speculative hype also because it's a pre-revenue company that's relying on continued positive trial updates and regulatory approvals that are not guaranteed.
Investors should remain wary of buying ProKidney stock at current levels also because it's already trading near analysts' average price target.
While the consensus rating on PROK shares remains at 'Moderate Buy,' the mean target of $4.33 is below its current trading price.
On the date of publication, Wajeeh Khan did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 hours ago
- Yahoo
Apple Expects $1.1 Billion Tariff Hit in 4th Quarter After $800 Million Q3 Hit; CEO Tim Cook Warns ‘Many Factors That Could Change'
Apple CEO Tim Cook used part of the company's fiscal Q3 2025 earnings call to address a growing cost pressure that has little to do with supply chains or raw materials, and everything to do with geopolitics: tariffs. Cook disclosed that Apple (AAPL) absorbed roughly $800 million in tariff-related costs during the June quarter and expects that figure to climb to $1.1 billion in the September quarter, assuming no changes to current global tariff policies. More News from Barchart Lyft Generates Huge FCF Margins - LYFT Stock Is Too Cheap Powell, Trump Talks and Other Can't Miss Items this Week 'My Kid Will Never Ever Be Smarter Than an AI': OpenAI's Sam Altman Warns Most Kids Won't Know a World Without AI Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! 'Finally, the situation around tariffs is evolving, so let me provide some color there,' Cook told investors. 'For the June quarter, we incurred approximately $800 million of tariff-related costs. For the September quarter, assuming the current global tariff rates, policies and applications do not change for the balance of the quarter and no new tariffs are added, we estimate the impact to add about $1.1 billion to our costs.' Trade Tensions Pressure Margins The acknowledgment of higher tariff costs highlights the headwinds Apple faces from ongoing trade disputes and shifting policy environments. With global supply chains deeply intertwined — especially in China, where much of Apple's manufacturing still occurs — tariffs can significantly squeeze operating margins. Cook stopped short of detailing which product lines or geographies are most affected, but warned that projecting beyond the September quarter is difficult. 'This estimate should not be used to make projections for future quarters as there are many factors that could change, including tariff rates,' he clarified. Investor Concerns: Impact on Pricing and Profitability For investors, the tariff discussion raises immediate questions: Will Apple absorb the increased costs and take the hit to margins, or will it pass some of the burden on to consumers through higher prices? Historically, Apple has attempted to shield its customers from sudden price jumps on flagship products, instead optimizing its supply chain or adjusting regional pricing strategies to offset trade friction. However, a $1.1 billion quarterly cost increase is significant enough to potentially influence gross margin guidance in upcoming quarters. Geopolitical Risk in Focus The warning underscores Apple's ongoing exposure to geopolitical risk, especially as trade policies between the U.S., China, and other manufacturing hubs remain volatile. Apple has made progress in diversifying its production footprint into countries like India and Vietnam, but the scale of those operations still lags behind its exposure to China. If tariffs persist or expand, Apple may face renewed pressure to accelerate diversification — a move that could require additional capital expenditures and take years to fully implement. Macro Context The global tariff landscape remains fluid, with recent policy debates in both Washington and Beijing signaling that tech products are likely to remain in the crosshairs of trade negotiations. For Apple, the stakes are high; any escalation in tariffs could weigh on both earnings and investor sentiment, particularly if cost pressures coincide with weaker consumer demand. While the September quarter estimate offers a concrete figure, Cook's caution about unpredictability serves as a reminder that trade-related costs could swing significantly from quarter to quarter. For now, Apple appears poised to manage the increase without disrupting its product release cadence — but any major policy shifts could change that calculus quickly. On the date of publication, Caleb Naysmith did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Sign in to access your portfolio
Yahoo
a day ago
- Yahoo
Are Wall Street Analysts Predicting Lamb Weston Stock Will Climb or Sink?
Eagle, Idaho-based Lamb Weston Holdings, Inc. (LW) engages in the production, distribution, and marketing of frozen potato products. It offers frozen potatoes, commercial ingredients, and appetizers under the Lamb Weston brand, as well as under various customer labels. With a market cap of $7.5 billion, Lamb Weston's operations span North America and internationally. The company has significantly underperformed the broader market over the past year. LW stock has plunged 11.4% over the past 52 weeks and nearly 19% on a YTD basis, compared to the S&P 500 Index's ($SPX) 16.4% gains over the past year and 9.7% returns on a YTD basis. More News from Barchart Lyft Generates Huge FCF Margins - LYFT Stock Is Too Cheap Powell, Trump Talks and Other Can't Miss Items this Week 'My Kid Will Never Ever Be Smarter Than an AI': OpenAI's Sam Altman Warns Most Kids Won't Know a World Without AI Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! Narrowing the focus, Lamb Weston has also underperformed the sector-focused Consumer Staples Select Sector SPDR Fund's (XLP) 2.2% uptick over the past 52 weeks and 4.3% gains in 2025. Lamb Weston Holdings' stock prices inched up 1.1% following the release of its impressive Q4 results on Jul. 23. In the second half of the fiscal 2025, the company gained a solid momentum of customer wins and retention, which boosted its topline performance. The company's net sales for the quarter grew nearly 4% year-over-year to $1.7 billion, surpassing the Street expectations. Furthermore, the company reported a notable 8% growth in adjusted net income to $122.8 million and 11.5% growth in adjusted EPS to $0.87, exceeding the consensus estimates by 35.9%. For the full fiscal 2026, ending in May 2026, analysts expect LW to deliver an adjusted EPS of $3, down 10.5% year-over-year. The company has a mixed earnings surprise history. While it surpassed or matched the Street's bottom-line estimates in three of the past four quarters, it missed the projections on one other occasion. The stock has a consensus 'Moderate Buy' rating overall. Of the 12 analysts covering the LW stock, opinions include four 'Strong Buys' and eight 'Holds.' This configuration has remained stable in recent months. On Jul. 25, Barclays (BCS) analyst Andrew Lazar reiterated an 'Overweight' rating on LW stock and raised the price target from $61 to $68, suggesting a 25.6% premium to current price levels. As of writing, Lamb Weston's mean price target of $62.82 suggests a 16% upside potential. On the date of publication, Aditya Sarawgi did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Yahoo
a day ago
- Yahoo
Do Wall Street Analysts Like The Allstate Stock?
Northbrook, Illinois-based The Allstate Corporation (ALL) provides property and casualty, and other insurance products in the United States and Canada. With a market cap of $54.5 billion, Allstate operates through Allstate Protection, Protection Services, Health and Benefits, Run-off Property-Liability, and Corporate and Other segments. The insurance giant has marginally underperformed the broader market over the past year. ALL stock has gained 16.1% over the past 52 weeks and 7.3% on a YTD basis, compared to the S&P 500 Index's ($SPX) 16.4% gains over the past year and 9.7% returns on a YTD basis. More News from Barchart Lyft Generates Huge FCF Margins - LYFT Stock Is Too Cheap Powell, Trump Talks and Other Can't Miss Items this Week 'My Kid Will Never Ever Be Smarter Than an AI': OpenAI's Sam Altman Warns Most Kids Won't Know a World Without AI Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. Narrowing the focus, Allstate has also underperformed the sector-focused Financial Select Sector SPDR Fund's (XLF) 20.7% surge over the past 52 weeks and 8.6% gains on a YTD basis. Allstate's stock prices shot up 5.7% in a single trading session following the release of its impressive Q2 results on Jul. 30. The company reported solid 7.5% year-over-year growth in premiums earned, reaching $14.3 billion. Further, it reported a notable improvement in net investment income, and its overall topline for the quarter came in at $16.6 billion, up 5.8% year-over-year. Meanwhile, Allstate observed a massive growth in profits. Its non-GAAP adjusted net income for the quarter soared 270.9% year-over-year to $1.6 billion, and its adjusted EPS for the quarter came in at $5.94, beating the consensus estimates by 78.9%. For the full fiscal 2025, ending in December, analysts expect Allstate to deliver an adjusted EPS of $20.84, up 13.8% year-over-year. Further, the company has a robust earnings surprise history. It has surpassed the Street's bottom-line projections in each of the past four quarters by notable margins. The stock maintains a consensus 'Moderate Buy' rating overall. Of the 23 analysts covering the stock, opinions include 15 'Strong Buys,' one 'Moderate Buy,' five 'Holds,' and two 'Strong Sells.' This has remained mostly stable in recent months. On Aug. 11, Jefferies analyst Andrew Andersen maintained a 'Buy' rating on Allstate and raised the price target from $254 to $255. As of writing, ALL's mean price target of $230.95 suggests an 11.7% upside potential. Meanwhile, the street-high target of $275 represents a 33% premium to current price levels. On the date of publication, Aditya Sarawgi did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Sign in to access your portfolio
